Inhibitors of Amyloid Toxicity Based on β-sheet Packing of Aβ40 and Aβ42
Open accessAbstract
Amyloid fibrils associated with Alzheimer's disease and a wide range of other neurodegenerative diseases have a cross beta-sheet structure, where main chain hydrogen bonding occurs between beta-strands in the direction of the fibril axis. The surface of the beta-sheet has pronounced ridges and grooves when the individual beta-strands have a parallel orientation and the amino acids are in-register with one another. Here we show that in Abeta amyloid fibrils, Met35 packs against Gly33 in the C-terminus of Abeta40 and against Gly37 in the C-terminus of Abeta42. These packing interactions suggest that the protofilament subunits are displaced relative to one another in the Abeta40 and Abeta42 fibril structures. We take advantage of this corrugated structure to design a new class of inhibitors that prevent fibril formation by placing alternating glycine and aromatic residues on one face of a beta-strand. We show that peptide inhibitors based on a GxFxGxF framework disrupt sheet-to-sheet packing and inhibit the formation of mature Abeta fibrils as assayed by thioflavin T fluorescence, electron microscopy, and solid-state NMR spectroscopy. The alternating large and small amino acids in the GxFxGxF sequence are complementary to the corresponding amino acids in the IxGxMxG motif found in the C-terminal sequence of Abeta40 and Abeta42. Importantly, the designed peptide inhibitors significantly reduce the toxicity induced by Abeta42 on cultured rat cortical neurons.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Solid-state nuclear magnetic resonance analysis demonstrated direct binding of an 8 aa peptide containing the sequence FEGKF with the glycine zipper (G33xxxG37) segment of A1-40, a sequence proposed to be critical for formation and stability of -sheet structure.
“Moreover, solid-state nuclear magnetic resonance analysis demonstrated direct binding of an 8 aa peptide containing the sequence FEGKF with the glycine zipper (G33xxxG37) segment of A1-40, a sequence proposed to be critical for formation and stability of -sheet structure (Liu et al., 2005;Sato et al., 2006).”
From BRI2 (ITM2b) Inhibits A Deposition In Vivo (2008) · cites this paper as Sato et al., 2006
Bri2-23 contains the sequence FENKF that is homologous to peptide-based A aggregation inhibitors incorporating a FxxxF motif.
“In support of our observations, Bri2-23 contains the sequence FENKF that is homologous to peptide-based A aggregation inhibitors incorporating a FxxxF motif (Sato et al., 2006).”
From BRI2 (ITM2b) Inhibits A Deposition In Vivo (2008) · cites this paper as Sato et al., 2006
Cites
Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C., & Glabe, C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48529-8 · Cited by 1,014 · see citing works
Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand
Tjernberg, L. O., Näslund, J., Lindqvist, F., Johansson, J., Karlström, A. R., Thyberg, J., Terenius, L., & Nordstedt, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8545 · Cited by 963 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Why is the amyloid beta peptide of Alzheimer’s disease neurotoxic?
Rauk, A. (2008) · Dalton Transactions · doi:10.1039/b718601k · Cited by 139 · see citing works
BRI2 (ITM2b) Inhibits A Deposition In Vivo
Kim, J., Miller, V. M., Levites, Y., West, K. J., Zwizinski, C. W., Moore, B. D., Troendle, F. J., Bann, M., Verbeeck, C., Price, R. W., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0891-08.2008 · Cited by 113 · see citing works
The roles of GxxxG motif and gamma-secretase components in APP processing
Kim, J. (2009) · Interdisciplinary Bio Central · doi:10.4051/ibc.2009.4.0015 · Cited by 3 · see citing works
- Authors
- Sato, T., Kienlen-Campard, P., Ahmed, M., Liu, W., Li, H., Elliott, J. I., Aimoto, S., Constantinescu, S. N., Octave, J.-N., & Smith, S. O.
- Affiliations
- Brookhaven National Laboratory (US)
- Department of Biochemistry and Cell Biology, Center for Structural Biology, Stony Brook University, Stony Brook, New York 11794-5215, Experimental Pharmacology Unit, Université Catholique de Louvain, Brussels 1200, Belgium, Department of Biology, Brookhaven National Laboratory, Upton, New York, Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan, and Ludwig...
- Corresponding author
- Smith, Steven O.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-04-07
- Volume
- 45
- Issue
- 17
- Pages
- 5503-5516
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2593882
- OpenAlex
- W2004400100
- Cited by
- 191
- References
- 2
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 8 · 2018: 3 · 2017: 6 · 2016: 8 · 2015: 12 · 2014: 7 · 2013: 16 · 2012: 16
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Funders
- National Institutes of Health (1s10rr013889-01)
- National Institute on Aging (R01AG027317)
- National Institute of General Medical Sciences (GM46732, T32GM008444, R01GM046732)
- National Center for Research Resources (S10 RR 13889)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- amyloid-beta, Alzheimer's disease, Aβ40, amyloid-beta 42, peptide inhibitors, fibril formation, neurotoxicity, cortical neurons
- MeSH terms
- Amino Acid Sequence, Amyloid, Animals, Fluorescent Dyes, Glycine, Humans, Methionine, Microscopy, Electron, Molecular Sequence Data, Neurons, Oligopeptides, Peptide Fragments, Spectrometry, Fluorescence, Thiazoles, Amyloid beta-Peptides, Protein Structure, Secondary, Protein Structure, Tertiary, Nuclear Magnetic Resonance, Biomolecular, Rats, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review